Nektar reports Phase Ib data for NKTR-214/Opdivo combo in cancer

Nektar Therapeutics (NASDAQ:NKTR) reported interim response data from the dose-escalation Phase Ib portion of the Phase Ib/II PIVOT-02 trial evaluating NKTR-214 plus Opdivo nivolumab to treat advanced or metastatic solid tumors at the Society for Immunotherapy of

Read the full 372 word article

User Sign In